about
Modulation of tumor necrosis factor by microbial pathogens.Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growthT cells down-regulate macrophage TNF production by IRAK1-mediated IL-10 expression and control innate hyperinflammationPlasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine.TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.Mast cells are an essential hematopoietic component for polyp development.Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats.Host-mediated resolution of inflammation in periodontal diseases.Inflammation in prostate carcinogenesis.Treating very early rheumatoid arthritisVaccination with cytokines in autoimmune diseases.BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats.Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.Mast cells: a new target in the treatment of complex regional pain syndrome?The antifibrogenic effect of etanercept on development of liver cirrhosis induced by thioacetamide in rats.Report of a preliminary discontinued double-blind, randomized, placebo-controlled trial of the anti-TNF-α chimeric monoclonal antibody infliximab in complex regional pain syndrome.Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases.Tumour necrosis factor-alpha blockade suppresses murine allergic airways inflammation
P2860
Q21089629-90558E03-E045-4C08-A290-F9BB5EC0E440Q27300769-B6739184-9258-454E-BDED-4E193E4FA339Q28504567-5CE375B2-F6EF-4BB3-AD0E-A2541D535A0CQ33563398-E9FDA4C6-5411-4860-B973-BE97709998D9Q36121743-4B0EB458-8FC6-4878-8568-236596BAC757Q36288986-DB71D4B1-F437-4182-82B0-97019E25146BQ36357902-E53A4DE7-336A-43AA-ABD4-97E51974D54CQ36362712-2B5A2077-3FFD-4F9F-88E7-4F20391A49B6Q36554784-AC87CDFC-A661-41E3-BADF-63F5D1551195Q36596130-512663A4-BB9E-449C-9162-70EE03A1E73DQ37165366-630E16E7-1633-4740-A50E-8D554EDBFD01Q37728305-12EF5DFF-98F5-4EFE-A028-83942BAE7916Q37773243-E4EFA601-C086-466C-B930-1E127EDD577DQ38089303-7CDAFEB1-BE97-447D-8DFB-84C74CC985FBQ46407865-9ACF72B0-C51D-4508-96BE-66CB53BF05B7Q48239224-3BE622E1-B224-4B96-A1DF-48A2660A02F0Q55305483-CFBE23C1-8125-42D0-B82A-C5546698FC1FQ57232016-9D93268D-274D-4FB6-8AE9-4A350836B7F1
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
TNF-blocking therapies: an alternative mode of action?
@ast
TNF-blocking therapies: an alternative mode of action?
@en
type
label
TNF-blocking therapies: an alternative mode of action?
@ast
TNF-blocking therapies: an alternative mode of action?
@en
prefLabel
TNF-blocking therapies: an alternative mode of action?
@ast
TNF-blocking therapies: an alternative mode of action?
@en
P2093
P50
P356
P1433
P1476
TNF-blocking therapies: an alternative mode of action?
@en
P2093
Andrew J Leishman
Brian S W Choo-Kang
Mohammad B Nickdel
Paul Garside
Robert V Bundick
P304
P356
10.1016/J.IT.2005.07.007
P577
2005-10-01T00:00:00Z